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Abstract: Recent reports of strong selection of mito-
chondrial DNA (mtDNA) during transmission in animal
models of mtDNA disease, and of nuclear transfer in both
animal models and humans, have important scientific
implications. These are directly applicable to the genetic
management of mtDNA disease. The risk that a mito-
chondrial disorder will be transmitted is difficult to
estimate due to heteroplasmy—the existence of normal
and mutant mtDNA in the same individual, tissue, or cell.
In addition, the mtDNA bottleneck during oogenesis
frequently results in dramatic and unpredictable inter-
generational fluctuations in the proportions of mutant
and wild-type mtDNA. Pre-implantation genetic diagnosis
(PGD) for mtDNA disease enables embryos produced by in
vitro fertilization (IVF) to be screened for mtDNA
mutations. Embryos determined to be at low risk (i.e.,
those having low mutant mtDNA load) can be preferen-
tially transferred to the uterus with the aim of initiating
unaffected pregnancies. New evidence that some types of
deleterious mtDNA mutations are eliminated within a few
generations suggests that women undergoing PGD have
a reasonable chance of generating embryos with a lower
mutant load than their own. While nuclear transfer may
become an alternative approach in future, there might be
more difficulties, ethical as well as technical. This Review
outlines the implications of recent advances for genetic
management of these potentially devastating disorders.
Introduction
One in 400 people carries pathogenic mitochondrial DNA
(mtDNA) mutations [1]. These may cause epilepsy, liver failure,
cardiomyopathy, or sudden death; or, more commonly, milder
disorders such as age-related deafness [1] and/or diabetes [2] and
loss of vision [3]. Yet, management and prevention of mtDNA
diseases has lagged far behind the genetics revolution [4].
Although preimplantation genetic diagnosis (PGD) has been
successfully used to prevent transmission of mtDNA disease
[5,6], its use has been limited for several reasons that are
developed in the following sections. Technical improvements in
methods for nuclear transfer [7,8] have aroused expectations of
preventing transmission of these disorders, but is this method safe?
Dose of Mutant mtDNA Determines Severity:
Implications for Prenatal Genetic Diagnosis
Chorionic villus sampling (CVS, where early placental tissue is
sampled with minimal impact on the foetus) has been extremely
successful in preventing recurrence of Mendelian genetic diseases,
but not for maternally inherited diseases, caused by mutations in
the mtDNA, because of the problem of heteroplasmy [9,10].
Thousands of mtDNA copies are present in every nucleated cell.
Normal individuals are homoplasmic (i.e., virtually all their
mtDNA copies are identical), but individuals affected by mtDNA
diseases are usually heteroplasmic: most of their tissues and cells
have a mixture of both normal and mutant mtDNAs. There is also
a threshold effect (tissues function normally unless the proportion
of mutant mtDNA rises above a particular level) in most diseases.
The level of this threshold varies with both tissue and mutation
type, usually in the range 50 to 100% mutant mtDNA, but
occasionally as low as 10% [11]. Hence, for many mtDNA
mutants, disease might be prevented by selecting embryos or
actively lowering the level of mutant mtDNA (for instance by using
nuclear transfer). But this is not universally applicable, because
some mtDNA diseases are commonly homoplasmic and lack a
clear threshold [12].
Unique Inheritance of mtDNA: Heteroplasmy and
the Mitochondrial Bottleneck
Heteroplasmy is one reason why the clinical severity of mtDNA
disorders is highly variable and can progress with time. In mtDNA
disease patients the level of mutant mtDNA commonly [13,14]
(but not always [15]) falls in blood throughout life (perhaps as a
result of selection against detrimental mutant mtDNA within a
rapidly dividing population of cells [13,16]). There are a few case
reports suggesting that some types of mtDNA mutant accumulate
in non-dividing cells such as muscle [14,17,18], where mtDNA
turnover is slow [19], and less subject to inter-cellular competition
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observations [21]. The progressive change in distribution of some
human mutants parallels the dynamic of apparently neutral
variants in blood and spleen in an animal model [22] and
underlines our inability to define the parameters determining the
characteristics that we have loosely termed ‘‘detrimental.’’ The
scanty available evidence suggests that there is less segregation in
somatic tissues between early embryo and birth than post-natally
[10,23]. However, a major component of the germline segregation
during transmission of both human [24] and mouse polymor-
phisms probably occurs during oogenesis [23,25], and hence
during development of the mother, apparently while she was in
utero herself.
Factors that affect segregation of mtDNA variants include the
biological fitness of dividing cells, the mutant load, and any
differences between wild-type and mutant mtDNA in the rate of
replication and degradation. While accumulation of mutant
mtDNA can sometimes be attributed to genetic drift [26],
consistent segregation towards loss or gain of mutant mtDNA
has been widely documented in human cultured cells [27–29].
Some mutant mtDNAs exhibit segregation in the opposite
direction to that predicted on the basis of selection according to
mitochondrial function [28,30–33]. Moreover, biased mtDNA
segregation has been demonstrated in solid tissues of mice [22].
Two mouse mtDNA variants were selected in different tissues as a
result of differences in genetic background [32,33], even though
neither was associated with a marked functional defect [22], nor a
detectable difference in mtDNA replication rate [22]. Because
differences in production of reactive oxygen species (ROS) affect
mtDNA copy number [34], they may contribute to segregation of
heteroplasmic mutants.
Analysis of segregation of mtDNA mutants in tissue culture
often uses ‘‘cybrid’’ technology, where mtDNA-free immortalized
cells are fused with cytoplasm containing the mitochondria under
investigation. Because such cells are aneuploid, some investigators
dismiss this model as non-physiological [35]. However, it does
indicate that several factors might underpin mtDNA segregation
in cell lines, including cellular fitness, replication pausing, ROS
production, and mitophagy (preferential breakdown and recy-
cling of regions of the mitochondrial reticulum of organelles
containing mutant mtDNAs) [29,36–39]. It is now increasingly
possible to test the validity of such hypotheses in whole animals
[32,33].
Genetic counseling of women who are carriers of mtDNA
diseases is complex because the dose of mutant mtDNA
transmitted to offspring may be determined by the so-called
‘‘mitochondrial bottleneck’’ [40,41], whereby a small number of
mtDNAs become the founders for the offspring. If the number
of segregating units (groups of clonal mtDNAs that co-segregate)
that become the mtDNA founders of the embryo is small, then
large fluctuations may occur in a single generation. Hauswirth
and Laipis [42–44] suggested that two components to this may
occur at different developmental stages. Firstly, there is a
massive expansion from ,100 mtDNA genomes in the earliest
stages of oocyte development or primordial germ cell (PGC) to
100,000 or so in the mature oocyte [42]. Mitochondrial DNA
barely replicates during the early stages of development [45]
and pre-existing mtDNA molecules segregate among the cells of
the blastocyst [43,46–49]. This represents a second mechanism
contributing to switching in the proportion of mutant mtDNAs,
since mtDNAs are progressively partitioned at each cell division,
ultimately producing the very few cells that will give rise to the
entire embryo (the inner cell mass) [42,44]. Hence, both clonal
proliferation of mtDNA in the developing oocyte and mtDNA
segregation during early development contribute to the
bottleneck.
Is the Bottleneck Determined by mtDNA Content
in Germ Cell Development? Mouse Studies
Recent studies have carefully quantified mtDNA copy number
of individual cells during mouse development [49,50–52]. As
predicted [49,53], the number of mtDNA copies drops to ,200
molecules in developing PGCs until embryonic day (E) 7.5-8.5
[52], corresponding to the number of segregating units inferred
from postnatal analysis [47,53]. There is, however, conflicting data
suggesting that copy number does not fall to values lower than
1,000 in PGCs until E7.5 in mice [50,51]. As well as depending on
technically demanding measurements of the number of mtDNAs
in single cells [50,51], these models have assumed both that
segregation in the germline is neutral [54] and that all mtDNA
genomes have equal probability of replicating during a single
round of cell division. Such assumptions may not be valid, since
Wai et al. [52] showed that a sub-population of mtDNAs replicates
during folliculogenesis in mice, replenishing the mtDNA content
in oocytes and potentially explaining the shifts in mutant load
between two generations (Figure 1). While this might explain the
variance in mutant load that these authors found in oocytes [52], a
more sophisticated analysis demonstrates that a larger set of
biological data is needed to establish their claim [55,56].
In humans, although the meiotic division is initiated in the
germline of the developing foetus during the last trimester of
pregnancy, primary oocytes remain arrested in the first stage of the
meiosis during the years between birth and puberty. In women of
reproductive age, a group of oocytes is selected to grow and resume
meiosis every cycle of ,28 days. In most cases this results in the
production of a single developmentally competent oocyte. It is
possible that clonal expansion of a subpopulation of mtDNA during
folliculogenesis in mice (between the stages of primary and mature
oocyte) may correspond to the mitochondrial bottleneck [52]. If this
is correct, then the segregating unit that is the physical basis of the
bottleneck might be the mitochondrial nucleoid, usually containing
several mtDNAs [57], rather than a single mtDNA molecule [49].
Understanding the nature of mtDNA packaging in nucleoids would
thentake onanewimportanceforbiology.Ontheotherhand,ifthe
mitochondrialbottleneckoccurs lateingermline development,what
is the purpose of the dramatic reduction in mtDNA copy number
reported during early development? Recent studies have suggested
it serves to preserve a homoplasmic population of predominantly
healthy mtDNA molecules by selecting against mtDNA mutations
that damage mitochondrial function (see below).
Selection against Detrimental mtDNA Mutants in
the Mouse Germline
Three studies suggest that there is selection against detrimental
mtDNA mutants in the mouse germline. One group developed a
mouse with mtDNA rearrangements modelling Kearns-Sayre
syndrome [58] in which the level of mutant mtDNAs in a mother’s
oocytes fell with time [59]. Like the occasional [60] mtDNA
rearrangements that are maternally transmitted [61], these mice
had mtDNA duplications in addition to deletions [59].
Another group investigated the transmission of randomly
generated mtDNA mutations in a mouse model of mtDNA
disease [62]. In this model, there is a mutation in the proof-reading
domain of the mtDNA polymerase, PolgA, and this generates high
levels of point mutations in the mtDNA. The homozygous founder
female mice were crossed with wild type and transmitted multiple
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mouse) to their offspring who were heterozygous for the PolgA
mutation. Subsequent backcrossing eliminated the mutant PolgA
allele and hence mtDNA mutants were passively transmitted
without generating further mutations. It was thus possible to
observe and compare the segregation of multiple different mtDNA
mutations in a single lineage. Neutral mutations that do not alter
the protein sequence undergo less selection than those that do.
Purifying selection can therefore be compared with neutral drift by
the relative frequency of such mutations. Clonal selection against
deleterious mutations occurred in a remarkably short time frame.
Indeed, many deleterious mutations were eliminated within four
generations. However, selection was stronger and occurred more
rapidly against mutations in genes encoding mRNAs than tRNAs.
This may be linked to the apparently high frequency of pathogenic
human mtDNA mutations that are identified in tRNAs [62].
A third study, focussing on two pathogenic mtDNA point
mutations, again demonstrates selection in mouse [63]. These
authors introduced mutant mtDNA from a well-characterised cell
line into the germline using cybrid technology and a female
embryonic stem cell line. Both the more severe frameshift
(insertion) mutation and the milder missense mutation were
initially homoplasmic, conferring a severe respiratory chain defect.
However, one of the embryonic stem (ES) cell clones became
heteroplasmic because a revertant of the frameshift mutation
arose; a secondary deletion of the adjacent base restored the
reading frame. When this line went into the germline, the mice
developed a sub-clinical myopathy and cardiomyopathy but bred
normally. The frameshift mutation was lost in favour of the
revertant within four generations. None of the offspring had a
higher level of the frameshift mutation than their mother, and
studies of oocytes showed that the selection had occurred by the
time oocytes were mature. These studies are consistent with other
studies on mice [52] and on humans [25,64]. The selection
appears to depend on some aspect of mitochondrial function, but
studies of the bottleneck have not clarified the precise mechanism
or at what stage of oogenesis it is likely to have occurred. While
some classic studies in humans [64,65] and in mice [53]
demonstrate that level of mutant mtDNA follows a distribution
that may be random [66], others are very different [23,30]. The
latter are skewed towards virtual homoplasmy for both mutant and
wild-type mtDNA in oocytes from individual women. One
explanation would be that a single mtDNA passes the bottleneck,
but there is no obvious mechanism for such an extreme situation.
Alternatively this could arise because genetic drift can lead to
fixation of neutral mutations [54]. While some investigators
consider that the different distributions may be due to the specific
mutation, we note that the skewed distributions have only been
seen following super-ovulation. Furthermore, close examination of
data suggest that the mean level of mutant mtDNA in the oocytes/
offspring is not identical with that of the mother, so germline
selection [59,62,63] is not excluded [54].
But what is the basis of the selection seen in mice and potentially
in humans? Only 30% of oogonia established during fetal life
develop into matured oocytes, the remainder undergoes apoptosis
[67,68]. Fan et al. [63] suggested that dysfunctional mitochondria
Figure 1. Mitochondrial DNA (mtDNA) copy number and genotypic variance throughout development in germ and somatic cells of
mammals. Although mtDNA genotypic variance in somatic cells increases early during development due to cellular differentiation, according to recent
findings this will only occur later in germ-line development, during folliculogenesis that takes place after birth. If this is correct, then the mitochondrial
genotype of the next generation would be defined only during adulthood, during the folliculogenesis that occurs every cycle of 28 days in women.
doi:10.1371/journal.pgen.1001066.g001
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against oocytes with high mtDNA mutant load by apoptosis.
A second possible mechanism for selecting against mutant
mtDNA is selection at the organelle level. The number of
mtDNA copies per mitochondrion in germ cells is thought to be
as few as one or two molecules, in comparison to eight or so in
somatic cells [57]. Thus, mutations in a few mtDNA copies can
be distinguished among wild-type mtDNAs present in the same
cell by the effect of mutations on mitochondrial phenotype. For
instance, damaged mitochondria might be degraded by intracel-
lular mechanisms such as autophagy or, more specifically,
mitophagy [36]. Evidences of this were given by Twig et al.
[69] who showed that dysfunctional mitochondria are less likely
to fuse with the remaining mitochondria and are degraded by
autophagy. Although this event was shown in somatic cells,
autophagy is also present in germ cells and early embryos [70]
and might be involved in removal of mutant mtDNA from the
next generation. Another possibility for selection at the organelle
level is competition between dysfunctional and normal mito-
chondria, where dysfunctional mitochondria might be less
efficient for import and enzymatic function of the nucleus-
encoded proteins that are required for mtDNA replication. This
might result in an advantage of wild-type molecules to replicate
over the mutant ones, thus decreasing the mutant load in germ
cells and in the next generation [71]. As discussed above, Wai
et al. [52] have reported that a sub-population of mtDNAs is
replicated during folliculogenesis to replenish the mtDNA content
in oocytes. If such a sub-population were positively selected on
phenotype by an unknown mechanism, this might explain the
observed pattern of selection against mtDNA mutations.
A third possible mechanism is specific to oocytes, based on a
structure known as the Balbiani body or the mitochondrial cloud
[72–74]. The Balbiani body comprises mitochondria and
endoplasmic reticulum organized around Golgi elements [73–
78] that may enable germplasm mRNAs to be specifically
inherited by the PGCs in the future embryo. In the same way, a
specific mitochondrial sub-population may segregate to the
Balbiani bodies and ultimately populate the PGCs [73,79–81],
potentially explaining the pattern of selection against severe
mtDNA mutations. In some non-mammalian species mitochon-
dria with the highest membrane potentials are found in Balbiani
bodies [78,80,81], suggesting that high-quality mitochondria and
mtDNAs are selected for transmission to the PGCs of the next
generation. While this is an appealing mechanism for selecting
against mutant mtDNAs, there is little supporting evidence and it
is still controversial, even in mouse [52]. Furthermore, the Balbiani
body could not explain the progressive decrease in load of mutant
mtDNA in mouse oocytes of an individual female with age.
Whatever the underlying mechanism, something occurring
during early oogenesis and/or folliculogenesis seems to provide a
degree of selection against mutant mtDNA molecules. Studies by
Sato et al. [59] and Fan et al. [63] suggest selection occurs during
adult life and, therefore, during folliculogenesis, since mutant load
drops in mouse oocytes as a function of time (i.e., between two
litters). On the other hand, mutations that escape this filter would
then be exposed to selection at the level of the individual. Thus,
several mechanisms may contribute to the bottleneck and prevent
dissemination of mtDNA mutations (Figure 2).
Mitochondrial DNA Bottlenecks in Human Germ
Cell Development
Genetic management of patients with mtDNA disease
depends on understanding both germline segregation and the
physiological basis of the bottleneck. However, the published
human data where oocytes are compared with load in maternal
post mitotic tissues are minimal [54]. It is increasingly clear that
a major component of this bottleneck has occurred by the time
oocytes are mature in human controls [25], patients with
mtDNA disease [64,82], and mouse models [52,53,63].
Statistical analysis of oocytes shows that in some cases the
distribution of mutant mtDNA is consistent with random drift,
but does not exclude the possibility of selection in the germline
at an earlier stage [66]. On the other hand, a de novo mutation
in a child and in oocytes appeared to be absent from the
mother’s other tissues [83], sugg e s t i n gt h a ti ta r o s ew i t h i nt h e
development of her germ cells. Comparison of human and
mouse data suggests potentially important differences in both
t h et y p eo fr e a r r a n g e m e n tt h a ti st y p i c a l[ 5 9 , 6 0 ]a n di nt h e
bottleneck size [55]. Hence, it may not be appropriate to
extrapolate from the consistent selection against detrimental
mtDNA mutants seen in the mouse [62] to humans.
Implications of Heteroplasmy for Genetic
Management of Human Diseases
Oocyte donation would avoid all the problems associated with the
presence of mutant mtDNA, but there is a shortage of oocyte donors.
Pre-implantation geneticdiagnosisformitochondrialdisease couldbe
the best option for patients carrying high levels of mutant mtDNA
[6]. This approach involves analyzing embryos produced by in vitro
fertilization(IVF)andonlytransferringthosedeterminedtobeatvery
low risk. Preimplantation genetic diagnosis is performed earlier in
development (three days after fertilization) than CVS, and two cells
are usually taken for mtDNA disease [6]. This is because analysis of
one or two cells from an embryo containing 6–10 cells may be more
representative of the whole conceptus [84], but not necessarily of the
part that will become the foetus. Moreover, sampling two cells rather
than only one provides a more confident result (the result from one
cellcan be compared againstthe other) and doesnot appear to impair
pregnancy outcome [6,85].
While PGD clearly has enormous promise for women with
sub-clinical levels of mtDNA mutations [6,23], it may be more
complex for women carrying high mtDNA mutation loads and
displaying disease symptoms [6,86]. If such women typically
transmit levels of mutant mtDNA close to their own [82,87],
they are likely to produce few if any disease free embryos. If,
however, the level of mutant mtDNA in their oocytes were
polarized to the two extremes as seen in neuropathy, ataxia and
retinitis pigmentosa (NARP) [23,30], they might have a
reasonable chance of usable embryos. This depends to what
extent the selection against detrimental mtDNA mutants that is
seen in mouse germline also occurs in humans. Nevertheless,
offering PGD for certain mtDNA diseases, followed by CVS to
confirm that the level of mutant mtDNA in the foetus is low,
would likely have advantages over CVS alone. The main
drawback of CVS for mtDNA disorders is that it is not entirely
certain that the level of mutant mtDNA detectable in a single
CVS sample will accurately refle c tt h a to ft h ef o e t u s[ 1 0 ] .
Indeed, such data that exist suggest that there is a degree of
variation of perhaps 610% in the level of neutral [88] and
pathogenic variants in placenta [83]. Moreover, certain centers
are now offering PGD [5,6,23].
Is Nuclear Transfer the Way Forward?
Since Dolly the sheep was created by fusing an adult somatic
cell with a recipient enucleated oocyte, producing in Dolly
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recipient oocyte [89], researchers have contemplated altering the
mitochondrial population of a human embryo using nuclear
transfer. It has been possible to use nuclear transplantation at the
zygote stage (pro-nuclear transfer) to partially correct respiration
defects and mitochondrial diseases in mice carrying a large-scale
deletion of mtDNA [90].
Recently, Tachibana et al. [8] transferred nuclei at an earlier
stage; spindle-chromosomal complexes were removed from
mature monkey oocytes, with minimal if any adherent mtDNA,
and placed into other oocytes from which the complex had been
removed. This study resulted in the generation of three healthy
offspring with less than 3% of nuclear donor mtDNA [8]. More
recently, Craven et al. [7] transferred pro-nuclei between human
zygotes resulting in minimal carry-over of nuclear donor mtDNA
and compatible onward development to the blastocyst stage in
vitro. Because of the current regulations and the paucity of
‘‘spare’’ human embryos, this study was carried out in abnormally
fertilized embryos. Disappointingly, the levels of nuclear donor
mtDNA were very variable between cells of the resulting embryos
(ranging from less than 0.5 to 11.4%), suggesting that mtDNA
segregation might be disturbed by the procedure. This may be a
consequence of using genetically abnormal embryos that would
not occur in bona fide treatment cycles. But it might be because
they used a drug that specifically targets the microtubule-based
system (nocodazole) for organizing mitochondria in the cell.
Despite this, both studies [7,8] (with their pros and cons) are of
fundamental importance and hold promise for the future
treatment of mtDNA diseases.
A different procedure, ooplasm donation (cytoplasm from a
donor oocyte), offers an alternative [91]. Ooplasm donation has
been used in humans as a treatment for poor IVF embryo
development for a type of infertility that might be due to intrinsic
defects of the oocyte cytoplasm. In this experimental procedure,
mitochondria, cytoplasm, and associated structures from a donor
oocyte are injected into a recipient unfertilised oocyte prior to
IVF. Mitochondrial DNA analysis of children born following the
procedure demonstrated that the contribution of donor mtDNA
is small [92], but, in some cases, the proportion of donor mtDNA
far exceeded the expected 10–15% [93], based on the volume of
cytoplasm derived from the donor. While genetic drift might
occasionally underlie such a change, experiments on bovine
zygotes suggest that mitochondrial replacement can be consis-
tently improved by centrifugation and removal of the recipient
mtDNA without apparent effects on development [94,95].
Centrifugation causes mitochondria to concentrate in one of
the zygote’s poles [94,95], allowing removal of mitochondrion-
enriched cytoplasm by micromanipulation. Doing this, it is
possible to remove over 60% of recipient-zygote mtDNA before
ooplasmic transfer [94]. Furthermore, the use of purified
mitochondria as donor mtDNA [96–98] might decrease the
mutant load to low levels, ultimately avoiding transmission of the
mitochondrial disorders.
Will any of these procedures be viable alternative strategies to
more conventional genetic management? Nuclear transfer sounds
simple and seems effective in mice [90], monkeys [8], and in
human pre-implantation embryos [7], yet there remain very many
unknowns. Mitochondrial DNA encodes only a handful of
Figure 2. Mitochondrial DNA (mtDNA) cycle in the mouse germline. During early embryo development (‘‘Segregation’’ on the diagram,
representing the first seven to eight days after fertilization) the mtDNA is segregated among daughter cells without being replicated. The number of
mtDNA copies thus decreases drastically, being lowest in primordial germ cells (PGCs). The next stage is marked ‘‘Replicative segregation,’’ which
implies random replication and partitioning of mtDNAs into daughter cells. The last stage, ‘‘Amplification,’’ is characterized by an exponential
amplification of mtDNA molecules. It has been suggested that replication of mtDNA during this stage is restricted to a sub-group of molecules
leading to drastic changes in the mtDNA genotype in the mature oocyte. Yet, there seems to be during this stage a selection against mutations in the
mtDNA that might occur.
doi:10.1371/journal.pgen.1001066.g002
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make up the mitochondrion being encoded by the nucleus. This
arrangement necessitates nucleo-mitochondrial interactions, which
are as yet poorly understood. In embryos derived either by nuclear
transfer or ooplasm donation, the genetic material originates from
three unrelated parents (two providing the nucleus and one the
mtDNA). While extreme (non-physiological) mismatch between
nuclear and mitochondrial DNA has clearly deleterious effects on
nucleo-mitochondrial interactions [99,100], might subtle errors in
these interactions occur following nuclear transfer? The conse-
quences of uncoupling the mitochondria and nucleus, followed by
the introduction of DNA from an unrelated individual are
unknown. Genetic studies of such interactions strongly suggest
that major problems are unlikely [32,33]. However, backcrossing
mice so that one mtDNA was substituted for another on a
standardized nuclear background can alter either physical [101] or
cognitive performance [102] and even the anatomy of the brain
[102]. Furthermore, studies on mice suggest that mtDNA carried-
over with the nuclear DNA of the donor zygote (karyoplast) may
be replicated faster than that of the recipient, perhaps depending
on its proximity to the nucleus [103]. Since nuclear transfer
experiments in multiple species show that donor mtDNA may
persist in embryos and tissues from the offspring [104], one cannot
assume that the mitochondria from the ‘‘healthy’’ enucleated
oocyte will ultimately outnumber the mutant mitochondria in the
tissues of the foetus and child. Furthermore, even in the best
hands, the success rate of achieving a pregnancy per egg is low and
donor oocytes are scarce.
Conclusion
In conclusion, the many ethical, scientific, and pragmatic
problems have been a major impediment in the genetic
management of mtDNA diseases. Recent experiments on animals
suggest that nuclear transplant holds future promise. Currently,
the most ethical course of action may be to weigh-up the
uncertainties and use new approaches such as PGD in an attempt
to help these distressed families.
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